Effects of Roxithromycin on Quality of Life and Physiological Outcomes in Bronchiectasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-01

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

roxithormycin 300 mg per day for 12 weeks could improve quality of life and physiological outcomes in bronchiectasis

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Azithromycin in Treatment of Bronchiectasis

NCT02107274

Bronchiectasis

COMPLETED PHASE4

Macrolide Mediates Pulmonary Infection of Pseudomonas Aeruginosa

NCT02491723

Bronchiectasis

COMPLETED NA

A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Exacerbations of Chronic Bronchitis With Levofloxacin Hydrochloride Tablet as Active Control

NCT02157571

Acute Exacerbations of Chronic Bronchitis

UNKNOWN PHASE3

A Study of the Effectiveness and Safety of High Dose, Short-course Levofloxacin in the Treatment of Acute Bacterial Exacerbation (Worsening) of Chronic Bronchitis.

NCT00042718

Bronchitis Chronic Bronchitis

COMPLETED PHASE3

An Open, Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin Versus Cefuroxime Alone or With Oral Erythromycin for the Treatment of Chinese Patients Who Were Hospitalized for Pneumonia

NCT00648726

Pneumonia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A randomized, double blinded, placebo controlled study was conducted to evaluate the effects of a 12-week administration of roxithromycin 300 mg once daily and a 12-week follow-up period in symptomatic stable bronchiectasis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Quality of Life Respiratory Function Tests

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

randomised control study

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

block of 4

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

roxithromycin

roxithromycin 300 mg oral per day

Group Type ACTIVE_COMPARATOR

Roxithromycin 300 MG

Intervention Type DRUG

Roxithromycin 300 mg oral per day

placebo

placebo one tablet per day

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo one table oral once dialy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Roxithromycin 300 MG

Roxithromycin 300 mg oral per day

Intervention Type DRUG

Placebo

Placebo one table oral once dialy

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Roxithromycin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Symptomatic bronchiectasis Stable clinical bronchiectasis

Exclusion Criteria

Adverse drug reaction to macrolide Recent exacerbation within 2 weeks History of macrolide therapy within 2 weeks active malignancy and end stage diseases 5. not perform lung function tests Females who were lactating

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No